CASE REPORT

Synovial sarcoma of the brachial plexus – a rare tumor in a rare area: a case report

Sreekanth Raveendran¹, Albert Abhinay Kota²*, Edwin Stephen², Samuel C. R. Pallapati¹ and Binu Prathap Thomas¹

Abstract

Background: Synovial cell sarcomas are usually seen in a juxta-articular location. However, they occur rarely in the head and neck region.

Case presentation: We report a rare case of brachial plexus synovial sarcoma in a 24-year old South Asian man treated successfully with surgical excision followed by radiotherapy.

Conclusions: Synovial sarcoma arising from the brachial plexus is rare. The treatment is multimodal with complete excision (often challenging owing to the proximity of the neurovascular structures) and adjuvant therapy.

Keywords: Synovial cell sarcoma, Soft tissue sarcoma, Brachial plexus

Background

Synovial sarcomas are malignant soft tissue tumors arising from mesenchymal cells, which resemble synovial cells [1]. They are likely to arise from undifferentiated mesenchymal stem cells and are seen near the large joints of the extremities [2, 3]. Very rarely, they are seen in areas remote from joints and synovial sheaths [4]. Head and neck areas are the most common regions.

Synovial sarcoma of the brachial plexus is extremely rare [5].

Fourteen cases of synovial sarcoma associated with a peripheral nerve have been reported [5]; only six were from the brachial plexus (Table 1) [5–10].

We report a case of synovial sarcoma of the brachial plexus abutting the subclavian artery. The tumor was successfully excised with no functional deficit or recurrence at 6 months. Information about this type of tumor in current medical literature is very limited and hence our work-up plan and treatment plan had to be formulated based on worldwide experience.

Case presentation

A 24-year-old South Asian man presented to our hospital with a progressively enlarging swelling that started on the left side of his neck and extended inferior to the clavicle (Fig. 1) increasing in size over a period of 6 months. His opposite upper limb and neck region were normal. He had no co-morbidities.

On examination a 10 × 12 cm globular, firm, non-pulsatile and immobile swelling was palpable on the left side of his neck. Tinel’s sign was negative on percussion. The lateral border of swelling was felt in the apex of axilla; it had smooth lobulated borders. He did not have any motor or sensory deficits. However, the brachial, radial, and ulnar artery pulses were absent. There was no locoregional lymphadenopathy and no metastasis. The clinical staging was stage 3 tumor (T3, N0, M0) according to the tumour, nodes and metastasis (TNM) classification.

Magnetic resonance imaging (MRI) showed a well-encapsulated 7.4 cm × 9.2 cm × 13.6 cm, ovoid-shaped, heterogeneous lesion in the left interscalene and posterior triangle, the costoclavicular space, and retropectoralis minor space with hypointense areas on T2/short T1 inversion recovery (STIR) and hyperintense with isointense areas on T1 with fluid levels (Fig. 2). Arterial duplex showed monophasic flow in his distal subclavian artery and vein. An ultrasound-guided biopsy proved the swelling to be synovial sarcoma with positive TLE1, epithelial membrane antigen (EMA), CD56 and CD57 with weak positive S100 and SYT–SSX1 translocation in immunohistopathology. At a multidisciplinary team (MDT) meeting with medical oncology it was suggested that excision of the lesion be attempted (in view of size and possibility of partial debulking surgery only)
followed by adjuvant chemotherapy and radiotherapy (RT).

**Procedure**
The mass was approached through a supraclavicular and infraclavicular approach to the brachial plexus with clavicle osteotomy. Immediately after the clavicle osteotomy the radial pulse was palpable. There was a good dissection plane between tumor and parts of the brachial plexus. The trunks, divisions, and cords of the brachial plexus were in contact with the superior and posterior borders of the mass. The mass arose from the C8 root and lower trunk; the tumor was successfully dissected out from the C8 root and lower trunk. The mass enveloped the mid and distal subclavian artery along its superior-posterior border (Fig. 3). The mass was excised as a whole from the subclavian artery leaving no lesion behind, macroscopically. After the excision of the mass, the clavicle was fixed with a 6-hole dynamic compression plate (DCP). His postoperative period was uneventful. The postoperative volume of the brachial, radial, and ulnar pulses was better than intraoperative volume.

The histopathology was reported as intermediate grade synovial sarcoma with SYT-SSX1 translocation in immunohistopathology. Since it was near marginal excision and the lesion was of intermediate grade, the oncology MDT meeting decided on adjuvant RT based on the National Comprehensive Cancer Network (NCCN) guidelines [11]. He underwent a full course of RT that included cobalt-60 gamma rays with dose delivered at 66 Gy to mid-plane in 33 fractions. Field size reduction was done after 46 Gy. At 6-month follow-up there were no clinical or radiological signs of recurrence.

**Discussion**
Synovial sarcoma accounts for 8% of soft tissue sarcomas [1, 4]. They are high-grade sarcomas and are treated with RT and adjuvant chemotherapy [12]. Three histological types are described, monophasic (fibrous or epithelial), biphasic, and the poorly differentiated (round) type [12]. They are typically seen in young adults [13] and have a better prognosis if they are small enough for marginal excision, with no metastasis, in the extremities, and with SYT-SSX1 rather than with SYT-SSX2 [3, 14].

| Case | Age | Sex | Nerves | Size | Treatment | Follow-up | Reference |
|------|-----|-----|--------|------|-----------|-----------|-----------|
| 1    | 44  | F   | C5–6 NR| 2 cm | Surgery f/b RT and chemotherapy | 1 year    | Tacconi et al. [6] (1996) |
| 2    | 11  | F   | C7 NR  | 0.5 cm | Surgery f/b RT | 3 years | Chu et al. [7] (2004) |
| 3    | 11  | F   | C7 NR  | –     | Surgery f/b chemotherapy and RT | 6 years Recurrence (mortality) | de Ribaupierre et al. [8] (2007) |
| 4    | 10  | M   | C8 NR  | 5.5 cm | Surgery f/b RT | 6 months | Ghiya et al. [5] (2011) |
| 5    | 53  | F   | Upper trunk | 4.5 cm | Surgery f/b RT and chemotherapy | 6 years | Pirouzmand et al. [9] (2012) |
| 6    | 18  | F   | C7 NR  | 5.9 cm | Surgery | – | Soomro et al. [10] (2016) |
| 7    | 24  | M   | C8 NR  | 13.6 cm | Surgery f/b RT | 6 months | Present case |

F female, f/b followed by, M male, NR nerve root, RT radiation therapy
Pluripotent mesenchymal stem cells give rise to synovial sarcomas rather than the synovial membrane, but the name, synovial sarcoma, is due to its resemblance. They have both spindle and epithelioid cells in the biphasic form but only one of them in the monophasic variant. The biphasic variant is easy to detect but the monophasic form has some close differentials like spindle cell carcinoma, hemangiopericytoma, leiomyosarcoma, fibrosarcoma, and melanoma. The use of tumor markers like keratin, vimentin, and EMA, and electron microscopy can confirm the diagnosis [9]. Chromosomal translocations between X and 18, t(X;18)(p11.2; q11.2) are also diagnostic [8, 9].

The goals have been to remove the tumor completely, to control the local growth of the tumor and prevent local recurrence/systemic metastasis. The best management protocol as per current literature for these rare tumors is surgical excision followed by RT. Excision with positive margins is a predictor of local recurrence [11]. Preoperative RT is associated with acute wound complications, hence postoperative RT is usually preferred [11]. NCCN guidelines recommend surgery followed by radiation therapy for stage 3 soft tissue sarcomas that are resectable with acceptable functional outcomes (Level 1 recommendation). The role of adjuvant chemotherapy is still debated and mostly reserved for high grade/unresectable tumors (2B recommendation) [11–13, 15, 16].

Bergh et al. reported survival rates at 5, 10, and 15 years of 60%, 50%, and 45% [12].

Our patient was a young man who benefitted from total surgical excision and postoperative RT. At a 6-month follow-up, there was no evidence of recurrence clinically and on MRI.

Conclusions
Synovial sarcoma arising from the brachial plexus is rare. The treatment is multimodal with complete excision (often challenging owing to the proximity of the neurovascular structures) and adjuvant therapy.

Authors’ contributions
SR, AK, and ES were the operating surgeons in the case. SR and AK did the manuscript writing/editing. ES, SCRP, and BPT were involved in manuscript editing. Overall responsibility – SR and AK. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Dr. Paul Brand Centre for Hand and Peripheral Nerve Surgery, Vellore, India. 2 Department of Vascular Surgery, Christian Medical College, Vellore 632004, India.

Received: 13 February 2018 Accepted: 28 September 2018
Published online: 09 November 2018

References
1. Carrillo R, Rodriguez-Peralto JL, Batsakis JG. Synovial sarcomas of the head and neck. Ann Otol Rhinol Laryngol. 1992;101(4):367–70. https://doi.org/10.1177/000348949210100415.
2. Kimura T, Wang L, Tabu K, et al. Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells. Oncogene. 2016;35(30):3932–43. https://doi.org/10.1038/onc.2015.461.
3. de Necochea-Campion R, Zuckerman LM, Mishahidi HR, Khosrowpour S, Chen C-S, Mishahidi S. Metastatic biomarkers in synovial sarcoma. Biomark Res. 2017;5:4. https://doi.org/10.1186/s40364-017-0083-x.
4. Hirsh RI, Yousem DM, Loeever LA, et al. Synovial sarcomas of the head and neck: MR findings. AJR Am J Roentgenol. 1997;169(4):1185–8. https://doi.org/10.2214/ajr.169.4.9308488.
5. Ghiya AV, Ketkar MN, Patankar S, Kothari S. A Rare Case of Synovial Sarcoma Involving the Brachial Plexus, Indian J Surg Oncol. 2011;2(1):24–6. https://doi.org/10.1007/s13193-011-0075-5.
6. Tacconi L, Thom M, Thomas DGT. Primary monophasic synovial sarcoma of the brachial plexus: report of a case and review of the literature. Clin Neurol Neurosurg. 1996;98(3):249–52. https://doi.org/10.1016/S0303-8467(96)00020-0.
7. Chu PG, Benhattar J, Weiss LM, Meagher-Villemure K. Intraneural synovial sarcoma: two cases. Mod Pathol. 2004;17(2):258–63. https://doi.org/10.1038/modpathol.3800048.
8. de Ribaupierre S, Vernet O, Beck-Popovic M, Meagher-Villemure K, Rilliet B. Cervical nerve root synovial sarcoma in a child with chromosomal (X;18) translocation. Case report and review of the literature. Pediatr Neurosurg. 2007;43(5):380–5. https://doi.org/10.1159/000106887.
9. Pirouzman F, Kommaraju K, Coddock KJ, Howarth D. Synovial sarcoma of the brachial plexus: case report. Neurosurgergy. 2012;70(5):1329–33; discussion 1333. https://doi.org/10.1227/NEU.0b013e318228e035.
10. Soomro NH, Zafar AA, Shariff AS, Rizvi SI, Hayee. Synovial Sarcoma in Supraclavicular Region with Brachial Plexus Compression; A Rare Tumor in This Area with Rare Presentation. J Islamabad Med Dent Coll. 2016;5(2):94–8.
11. von Mehren M, Randall RL, Benjamin RS, et al. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2018;16(5):536–63. https://doi.org/10.6004/jnccn.2018.0025.
12. Bergh P, Meis-Kindblom JM, Cherlinzino F, et al. Synovial sarcoma: identification of low and high risk groups. Cancer. 1999;85(12):2596–607.
13. Elber FC, Dry SM. Diagnosis and management of synovial sarcoma. J Surg Oncol. 2008;97(4):314–20. https://doi.org/10.1002/jso.20974.
14. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62(1):135–40.
15. Palmerini E, Staals EL, Alberghini M, et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer. 2009;115(13):2988–98. https://doi.org/10.1002/cncr.24370.
16. Lee N, Shin E. Treatment outcomes for patients with synovial sarcoma of the head and neck. Expert Rev Anticancer Ther. 2008;8(3):371–3. https://doi.org/10.1586/14737140.8.3.371.